Analysis of sodium phenylbutyrate and taurursodiol ...
The CENTAUR trial evaluated sodium phenylbutyrate and taurursodiol (PB and TURSO) for ALS, showing a 4.8-month longer median survival and 36% lower death risk compared to placebo. A post hoc analysis using PRO-ACT database external controls found a 10.39-month longer survival for PB and TURSO, suggesting a greater survival benefit than ITT analysis indicated.
Related Clinical Trials
Reference News
Analysis of sodium phenylbutyrate and taurursodiol ...
The CENTAUR trial evaluated sodium phenylbutyrate and taurursodiol (PB and TURSO) for ALS, showing a 4.8-month longer median survival and 36% lower death risk compared to placebo. A post hoc analysis using PRO-ACT database external controls found a 10.39-month longer survival for PB and TURSO, suggesting a greater survival benefit than ITT analysis indicated.